REG - hVIVO PLC - Director/PDMR Shareholding

hVIVOAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250602:nRSB9171Ka&default-theme=true

RNS Number : 9171K  hVIVO PLC  02 June 2025

 
hVIVO plc

("hVIVO", the "Company" or the "Group")

 

CEO & CFO Share Purchase

 

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO)
and the world leader in human challenge clinical trials, announces that on
Friday 30 May 2025, Yamin 'Mo' Khan, Chief Executive Officer and Stephen
Pinkerton, Chief Financial Officer, purchased shares in the Company as
detailed below:

 

 Director           No of shares purchased  Purchase Price  Resultant holding  Resultant holding as a % of the issued share capital
 Yamin 'Mo' Khan    1,100,000               8.9 pence       5,001,603          0.73%
 Stephen Pinkerton  683,232*                8.76 pence      750,596*           0.11%

 

*343,232 of these shares were purchased/are held by Mrs Dolores Pinkerton,
wife of Stephen Pinkerton

 

Commenting, Dr Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said:
"Friday's trading update clearly raised concerns for our shareholders, but we
remain confident in the continued growth of human challenge trials and the
overall prospects for hVIVO, and accordingly Stephen and I have increased our
shareholdings in the Company to demonstrate our continued confidence in the
growth prospects of the Group.

 

"We have our largest ever sales pipeline, including projects under discussion
that would represent some of our biggest ever value contracts for human
challenge trials, such as the world's first ever Phase 3 HCT. We have also
successfully targeted a more diversified revenue base and we remain very
excited about the growth prospects of our hLAB services as well as our new
revenue streams from CRS's early phase clinical trial services and participant
recruitment."

 

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson,

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus / Alice Woodings /                 +44 (0)7980 541 893 / +44 (0)7407 804 654/

+44 (0)7584 391 303
 Lianne Applegarth

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/)  (Ticker: HVO) is full-service Contract
Research Organisation (CRO) and the global leader in human challenge trials.
The company delivers end-to-end clinical development services to a diverse and
expanding client base, including seven of the world's ten largest biopharma
companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/)  brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development
Consulting and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment
via FluCamp (https://flucamp.com/) . Additionally, its five clinical sites
support outpatient Phase II and III trials, ensuring a seamless and
efficient pathway from discovery to late-stage development.

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name of PDMR                                                 Yamin Mo Khan
 2   Reason for notification

 a.  Position/Status                                              Chief Executive Officer
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         hVIVO plc
 b.  LEI                                                          213800VT5KBM7JLIV118
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification Code

                                                                  ISIN GB00B9275X97

 b.  Nature of the transaction                                    Purchase of Ordinary Shares
 c.  Price(s) and volume(s)                                       No. of Shares  Price

                                                            1,100,000      8.9

 d.  Aggregated information

     - Aggregated Volume                                          See above

     - Price
 e.  Date of the transaction                                      30 May 2025

 f.  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

See above

e.

Date of the transaction

30 May 2025

 

f.

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name of PDMR                                                 Stephen Pinkerton
 2   Reason for notification

 a.  Position/Status                                              Chief Financial Officer
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         hVIVO plc
 b.  LEI                                                          213800VT5KBM7JLIV118
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

     Identification Code

                                                                  ISIN GB00B9275X97

 b.  Nature of the transaction                                    Purchase of Ordinary Shares
 c.  Price(s) and volume(s)                                       No. of Shares  Price

                                                            683,232        8.76

 d.  Aggregated information

     - Aggregated Volume                                          See above

     - Price
 e.  Date of the transaction                                      30 May 2025

 f.  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

See above

e.

Date of the transaction

30 May 2025

 

f.

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBFLLBEQLFBBQ